Kura Oncology Business Summary

Kura Oncology, Inc. (KURA) is a commercial-stage biopharmaceutical company that generates revenue through product sales and a strategic global collaboration with Kyowa Kirin. Its primary business segment centers on precision medicines for cancer, specifically menin inhibitors and farnesyltransferase inhibitors (FTIs). The company’s financial model was transformed by the November 2025 FDA approval of its lead asset, Komzifti (ziftomenib), for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Under its partnership with Kyowa Kirin, Kura receives tiered double-digit royalties on international sales and shares 50/50 in U.S. profits, supported by a milestone-heavy structure worth up to $1.2 billion in total potential payments. Kura competes primarily against Syndax Pharmaceuticals (Revuforj), Johnson & Johnson (bleximenib), and Incyte, distinguishing itself in the market through Komzifti’s once-daily oral dosing and a favorable safety profile that avoids the boxed warnings for QTc prolongation associated with its closest competitors. The company is led by co-founder, President, and CEO Troy Wilson, Ph.D., J.D., whose track record includes co-founding and exiting successful biotech firms such as Intellikine (acquired by Takeda), Ambrx (acquired by J&J), and Araxes Pharma. Following a strategic leadership transition in January 2025, the executive team includes Chief Medical Officer Mollie Leoni, M.D., an oncology veteran previously with Kyowa Kirin, and Chief Scientific Officer Francis Burrows, Ph.D., who has overseen the company’s translational research since 2016. Kura’s strategic direction is further guided by a board of directors that includes Lead Independent Director Faheem Hasnain and commercial expert Diane Parks, known for her pivotal role in the launch of Yescarta at Kite Pharma. The firm maintains strong institutional support from prominent life science investors, including Matrix Capital Management and EcoR1 Capital.